RecruitingPhase 4NCT07695701

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Sponsor

Eidos Therapeutics, a BridgeBio company

Enrollment

150 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Amyloidosis Amyloid Cardiomyopathy Transthyretin Amyloidosis Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Summary

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Acoramidis (AG10) oral tablet for people with amyloid cardiomyopathy, amyloidosis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAcoramidis (AG10) oral tablet

Study drug is defined as acoramidis 712 mg (equivalent to 800 mg acoramidis hydrochloride) taken orally twice daily for 36 months of open label treatment.